Drug development program further strengthened with issuance of a new patent.
This patent claims the composition of an isolated polypeptide having phosphatonin activity. Phosphatonin is an endogenous polypeptide hormone, which regulates serum phosphate (PO4) levels that leads to the goal of this invention to normalize serum PO4 in the patients. For example, hyperphosphatemia, one of the most common complications associated with chronic kidney disease which is widely accepted as a critical cause of vascular calcification, could be treated with the composition claimed in the patent .
Yoshi Kumagai, Acologix's President and Chief Executive Officer, said, "We are pleased to have established broad patent protection for our compounds. The issuance of this patent further strengthens the underlying value within the company as we've continued to build a strong pipeline of drugs for unmet needs for diseases in osteo-renal area. We intend to continue expanding our intellectual property position in the United States and other regions all over the world."
Mr. Cengiz Tarhan, Managing Director of UCL Biomedica, said, "We are pleased to hear that Acologix is progressing so well with UCL's technology. This issuance of this patent coupled with the licensing agreement clearly demonstrates that the world class research that is being performed here at UCL can find useful commercial outlets in partnerships with innovative companies such as Acologix."
Acologix has issued and pending patents covering composition, use, and method relating to its product candidates in North America, Europe as well as several Asian countries.
Acologix is a privately held biopharmaceutical company focused on developing and commercializing novel therapeutics primarily for the treatment of metabolic disorders of kidney and bone that represent significant unmet medical needs. Founded in 1992, the company's research and development efforts are centered on the body's metabolism of minerals and extracellular matrix molecules. This has led to the identification of unique therapeutic candidates for product development and commercialization. Acologix is seeking strategic development, commercial partnerships and licensees with pharmaceutical and biotechnology companies for several of its programs.
Founded in 1826, University College London (UCL) is the Sunday Times University of the Year 2004 and the fourth-ranked UK university in the top 500 world universities for 2004 league table produced by the Shanghai Jiao Tong University.
UCL Biomedica has been created through the merger of UCL Ventures and Freemedic Plc. UCL Biomedica aims to generate income and create capital value for UCL through the commercial exploitation of the bioscience research base at UCL and its associated Institutes. The company represents the integration of two highly successful technology transfer offices. Founded in 1989, UCL Ventures was established to form the link between academia and industry for the development of scientifically and commercially valuable technologies arising from UCL. UCL Ventures returned over pounds Sterling 15 million to UCL. Freemedic was established in 1993 to commercialize the intellectual property and other rights and opportunities arising primarily from the Royal Free Campus of UCL's Medical School. Freemedic's profits since 1996, all of which have been donated to UCL and utilized for investment in the Royal Free Campus, have exceeded pounds Sterling 15 million.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Nov 1, 2004|
|Previous Article:||Palatin Technologies expands patent portfolio in the treatment of sexual dysfunction.|
|Next Article:||TransMolecular broadens patent portfolio for lead oncology products with fifth issued United States patent.|